뉴스

• D&D Pharmatech tumbles 18% after Pfizer halts ORALINK candidate [K-bio pulse] D&D Pharmatech shares dropped sharply after it was confirmed that development had been halted on an obesity drug candidate built with the company's technology. www.edaily.co.kr · 2026.08.06